General information
- TYTUŁ CardioCarePack - a package of modern solutions in monitored therapy for patients with heart rhythm disorders supporting the development of personalized medicine.
- Project number POIR.01.01.01-00-1196/19
- Category R&D Project
- Contractors LabExperts sp. z o.o.; Zakład Medycznej Diagnostyki Laboratoryjnej na Wydziale Farmaceutycznym, Gdański Uniwersytet Medyczny
- Years of implementation 2020-2023
- OECD classification Medical sciences and health sciences.
- Localization Gdańsk, Łódź
CardioCarePack
Consortium LabExperts Ltd. and the Medical University of Gdansk is implementing the European Funds-funded project CardioCarePack – a package of state-of-the-art solutions for monitored therapy in patients with heart rhythm disorders to support the development of personalized medicine.
The aim of the project is innovative and personalized therapy of cardiac arrhythmias. The planned R&D work will include the development of a nationally innovative package of methods allowing precise and effective determination of concentrations of drugs used in the therapy of cardiac arrhythmias and a teleinformatics tool.
EU funding for the project: 6,905,836.43 PLN
Background of the project
Currently, therapy for cardiac arrhythmias includes drug saturation regimens that mainly take into account the patient’s body weight. Renal and hepatic function are also rarely taken into account. In contrast to the above, the patient’s metabolism is not taken into account. This parameter is sometimes crucial for antiarrhythmic drugs characterized by a narrow therapeutic index. As a result, the determination of too low a drug dose will be associated with a lack of therapeutic effect, which can lead to life-threatening conditions. Over-saturation of the blood with the drug can result in drug accumulation. This in turn leads to deterioration of liver function and renal failure. At present, TDM is gaining importance in the perspective of the number of cardiac arrhythmia cases. The problem in Poland is estimated at about 0.8 million people and in Europe at about 13 million people.
Subject of the project
As part of the project, we will conduct R&D work on the development of a nationally innovative solution package. As a result, we will have the ability to accurately and effectively determine the concentrations of drugs used in the treatment of cardiac arrhythmias (TDM, therapeutic drug monitoring – more information – 1, 2). TDM is defined as an activity aimed at optimizing pharmacotherapy in an individual patient. Monitoring is based on measurement of drug concentration in the blood, principles of pharmacokinetics and pharmacodynamic criteria.
Tasks
We are starting the project with TRL VI. As part of the planned work, we will complete 5 tasks to reach TRL IX. As a result, we will reach full readiness for commercialization.
Results
- Personalized medical diagnostics leading to increased patient safety.
- Highly accessible service – using dry capillary blood (VAMS – Mitra device), which the patient will collect at home.
- Software that will support the doctor in decision-making during pharmacotherapy.
- Access to medical history data by doctor and patient.
Target groups
We will commercialize the results of the work in the form of diagnostic services as a subcontractor to a network of analytical laboratories performing tasks for healthcare entities.
Keywords
Drug monitoring therapy, arrhythmia, cardiac arrhythmia therapy, antiarrhythmic drugs, atrial fibrillation, personalized medicine, therapeutic index.